David W. Addis

Schuyler Roche & Crisham (Chicago)
Of Counsel

David Addis’s latest position was Counsel at Schuyler, Roche & Crisham (previousely Schuyler, Roche & Zwirner). The firm recently closed. David Addis’s practice encompassed US foreign trade controls, including export controls, technology controls and encryption regulation, and antitrust counseling on mergers and acquisitions, joint ventures and other competitor collaborations, and intellectual property licensing, including IP licensing policies for standard-setting organizations. Mr. Addis has extensive experience with US foreign trade controls, export regulations and embargo sanctions administered by the Departments of Commerce, Treasury, State and Homeland Security, and advises on compliance, obtaining licensing, and responding to possible enforcement actions.


371 Bulletin

David W. Addis, James R. Dean, John Graubert, Timothy C. Hester, James J. O’Connell The US FTC adopts new rules clarifying HSR filing requirements for transfers of pharmaceutical patent rights


On November 6, the Federal Trade Commission (“FTC”) amended the implementation rules of the Hart Scott Rodino Antitrust Improvements Act (the “HSR Act”) to specify when parties to pharmaceutical patent license agreements must observe the HSR Act’s notification and pre-closing waiting period (...)

Thomas O. Barnett, James R. Dean, Deborah Garza, John Graubert, James J. O’Connell, Anita F. Stork, David W. Addis The US DoJ and FTC announce changes to the HSR Act merger notification process and transaction report form submitted by companies


On July 7, 2011, the Federal Trade Commission and the Department of Justice (“the Agencies”) announced significant changes to the form and accompanying materials that companies must submit when reporting transactions under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”). Although (...)

David W. Addis, Evan R. Cox, John Graubert, Theodore Voorhees Jr The US Court of Appeals for the DC Circuit holds that the avoidance of a RAND commitment leading to higher prices for licenses does not by itself amount to anticompetitive harm (Rambus)


On April 22nd, the DC Circuit Court of Appeals set aside the FTC’s 2006 decision that Rambus Inc. unlawfully monopolized four technology markets through deceptive conduct during the JEDEC standards development process for two widely-implemented computer memory standards. The Court held that (...)

Michael Labson, Geoffrey Hobart, Eric Holder, Mark Lynch, Richard Kingham, Peter Safir, Theodore Voorhees Jr, James R. Dean, David W. Addis, Ethan M. Posner The US FTC announces its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals


On April 4, 2006, the FTC published notice of its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals. See 71 Fed. Reg. 16,779 (April 4, 2006). The initial stage of the study would involve detailed information requests, akin to subpoenas, to as (...)


Total des visites

Nombre de lectures par contribution

Nombre de contributions

Classement de l'auteur
En nombre de contributions
En nombre total de visites
En nombre moyen de visites
Envoyer un message